Joubert syndrome-related disorders (JSRDs) are a group of clinically and genetically heterogeneous conditions that share a midbrain-hindbrain malformation, the molar tooth sign (MTS) visible on brain imaging, with variable neurological, ocular, and renal manifestations. Mutations in the CEP290 gene were recently identified in families with the MTS-related neurological features, many of which showed oculo-renal involvement typical of Senior-Löken syndrome (JSRD-SLS phenotype). Here, we performed comprehensive CEP290-mutation analysis on two nonoverlapping cohorts of JSRDaffected patients with a proven MTS. We identified mutations in 19 of 44 patients with JSRD-SLS. The second cohort consisted of 84 patients representing the spectrum of other JSRD subtypes, with mutations identified in only two patients. The data suggest that CEP290 mutations are frequently encountered and are largely specific to the JSRD-SLS subtype. One patient with mutation displayed complete situs inversus, confirming the clinical and genetic overlap between JSRDs and other ciliopathies.
Joubert syndrome (JS [MIM 213300])
is an autosomal recessive disease presenting with hypotonia, ataxia, neonatal breathing abnormalities, oculomotor apraxia, and psychomotor delay. 1, 2 The neuroradiological hallmark of JS is a complex midbrain-hindbrain malformation known as the "molar tooth sign" (MTS), which originates from the association of cerebellar vermis hypoplasia or aplasia, horizontally oriented and thickened superior cerebellar peduncles, and a deepened interpeduncular fossa. 3 These clinical and neuroradiological features are shared by at least eight distinct syndromes termed "JS-related disorders" (JSRDs), which additionally present with pleiotropic involvement, mainly of the eyes and kidneys. 4 The four major subgroups of JSRDs include (1) the classic form (MIM 213300), largely restricted to brain involvement and also occasionally displaying retinopathy and postaxial polydactyly but rarely renal involvement; The genetic bases of JSRDs are only partially under-stood. Two loci, JBTS1/CORS1 and JBTS2/CORS2, have been mapped to chromosomes 9q34.3 and 11p12-q13.3, respectively, in a limited number of families, [5] [6] [7] whereas mutations in the AHI1 gene have been shown to account for ∼10% of patients with JSRD, who mostly display the classic form of the disease. [8] [9] [10] [11] Recently, we and others identified pathogenic mutations in the CEP290 gene, which encodes a centrosomal protein, in 13 families with JSRD. 12, 13 CEP290 protein was localized to the base (centrosome) and stalk of primary cilia, suggesting that JSRDs constitute one of the "ciliarelated" group of disorders. This point is strengthened by the clinical overlap between JSRDs and other ciliopathies, including infantile and juvenile NPH (either isolated or associated with retinal dystrophy, which is known as "SLS"), Meckel syndrome (MKS [MIM 249000]), and Bardet-Biedl syndrome (BBS [MIM 209900]).
14 Further reinforcing this link, NPHP1 homozygous deletions that are a frequent cause of isolated juvenile NPH and SLS and mutations in MKS3 that are usually responsible for MKS have been detected in rare cases of JSRDs. [15] [16] [17] Among the 13 families with JSRD with CEP290 mutations reported so far, the majority had JSRD-SLS, in line with the pleiotropic features observed in most ciliopathies. Few patients displayed incomplete phenotypes lacking either renal or retinal involvement and additional signs, such as occipital encephalocele. 12, 13 Intriguingly, mutations in CEP290 have also been shown to be the most frequent cause of isolated LCA, in the absence of any renal and neurological involvement. 18, 19 The prevalence of CEP290 mutations among patients with JSRD-SLS, as well as their role in causing other MTSassociated phenotypes and genotype-phenotype correlates, are still unknown. In this study, we sought to address these issues by performing CEP290 mutation analysis in the largest series to date of probands representative of the whole JSRD clinical spectrum.
Subjects and Methods

Patient Ascertainment
Databases located at the IRCCS CSS, Mendel Institute (Rome) (AISJAC database), at the University of California-San Diego (San Diego) (Center for Cerebellar Malformations), and at the JS Foundation were screened for patients with a definite diagnosis of JSRD and neuroradiologically proven MTS. Patients were referred to these two centers from 120 countries on all continents through European and U.S. referral centers. Samples were obtained from referring physicians or through the JS BioBank. Whenever available, detailed clinical data were collected by means of a standardized questionnaire to assess the possible involvement of all organs, including diagnostic testing for ocular, renal, hepatic, and skeletal features.
From these databases, we selected two groups of patients for CEP290 screening. The first cohort consisted of 44 probands with definite or probable JSRD-SLS. Thirty-two patients met the following inclusion criteria for definite JSRD-SLS: (1) presence of MTS, (2) renal signs of NPH (end-stage renal disease [ESRD] and/ or typical ultrasound features and/or proof of impaired urinaryconcentration ability), and (3) either LCA or progressive retinitis pigmentosa. In this group, we also included 12 children younger than 10 years presenting a cerebello-ocular phenotype with MTS and LCA but with no obvious renal involvement, who had not yet undergone proper urinary-concentration testing or ultrasound examination. In our experience, the risk of a child with LCA within this age group developing a renal disease is 150%; thus, these 12 patients were given diagnoses of "probable JSRD-SLS."
The second cohort consisted of 84 probands representative of the complete spectrum of the remaining subgroups of JSRDs, including classic JS ( ), JS plus ocular involvement but n p 42 without renal involvement by age 10 years ( ), JS plus NPH n p 21 or cystic kidney disease without retinal involvement ( ), n p 5 COACH syndrome ( ), and OFDVI syndrome ( ). Five n p 6 n p 5 patients had a proven MTS, but clinical details were not sufficient to assign them to a specific phenotypic subgroup. Informed consent was obtained from all families, and the study was approved by the local ethics committees.
Mutational Analysis
The 128 probands with JSRD were analyzed for CEP290 mutations after a three-step strategy. 10 In brief, a denaturing high-performance liquid chromatography (DHPLC)-based analysis was first performed on DNA from one parent of each proband. All exons identified as carrying abnormal elution profiles were sequenced in both directions, and, subsequently, all parental mutations were tested in the affected offspring and, in case of homozygosity, in the other parent as well. Finally, heterozygous patients underwent complete gene analysis by direct sequencing in both directions to identify the second mutation. This strategy allowed DNA from affected children (which is usually scarce and difficult to reobtain) to be preserved and DHPLC limits in identifying homozygous mutations to be overcome. PCRs were performed in a final volume of 25 ml containing 40-80 ng genomic DNA, 1 U AmpliTaq Gold (Applied Biosystems), 15 pmol of each primer, 1.5-2 mM MgCl 2 , 75 mM of each deoxyribonucleotide triphosphate, and 1# PCR Buffer (Applied Biosystems), through the use of a GeneAmp PCR system 9700 (Applied Biosystems). Samples were run on a Wave DNA Fragment Analysis System (Transgenomics) at column temperatures recommended by Navigator Software version 1.5.4 (Transgenomics). Bidirectional sequencing of purified PCR products (Millipore) was performed by using BigDye chemistry and an ABI 3100 Capillary Array Sequencer (Applied Biosystems). Primers and conditions for PCR and DHPLC are listed in table 1.
The common NPHP1 homozygous deletion, the intronic CEP290 mutation recurring in isolated LCA (c.2991ϩ1655ArG), and mutations in the AHI1 gene were excluded in all probands, in accordance with published protocols.
10,16,18
Results
CEP290 Mutations
We identified 23 distinct CEP290 mutations in 21 families. Seventeen mutations were novel, whereas six had been reported elsewhere (tables 2 and 3). 12, 13, 19 Six probands were homozygous for CEP290 mutations, and 10 were compound heterozygous, whereas, in 5 probands, only a single mutated allele could be found. All mutations reported were either nonsense or frameshift mutations resulting in a predicted truncated protein. Most mutations (20 of 23) clustered from exon 28 to the end of the gene, with a peak at exon 41 ( fig. 1 ). The most common mutation was G1890X, which was homozygous in three families (two from the United Arab Emirates and one from Turkey) and heterozygous in three others (from Italy, Ireland, and the United Kingdom). The R1465X mutation in exon 34 recurred in three families (from Belgium, Brazil, and the United States), and the Q1628X (exon 37) mutation in two (from the United States and Russia), whereas the remaining 20 mutations were all found in single families (table 2) . All mutations segregated with the disease in familial cases. CEP290 nucleotide variants representing either polymorphisms or nucleotide changes of unknown significance are listed in table 4.
Phenotypes Associated with CEP290 Mutations
JSRD-SLS subgroup.-CEP290 mutations were identified in 16 (50%) of 32 probands with definite JSRD-SLS and in 3 (25%) of 12 patients with probable JSRD-SLS. All patients had neurological signs typical of JS and a neuroradiologically proven MTS ( fig. 2) . Fifteen had sporadic cases of disease, whereas four had one affected sib.
Among the 16 probands with definite JSRD-SLS, 15 presented with LCA and blindness within the 1st year of life, whereas only 1 (MTI154) had progressive retinitis pigmentosa, with visual reduction documented at age 6 years. One patient (MTI133b) had chorioretinal colobomas in addition to LCA. All patients had signs of infantile or juvenile NPH; the youngest was age 2 years. Eight of them had already developed ESRD at ages ranging between 4 and 18 years. Four patients with sporadic cases presented additional clinical features, including a small occipital encephalocele (COR083), atrial (COR003) or ventricular cardiac septal defect (MTI154), and complete situs inversus (MTI273) (fig. 3 ).
Three patients with mutations were given diagnoses of probable JSRD-SLS, since they had LCA but no overt signs of renal involvement by ages 2, 6, and 10 years. However, evaluation of urinary-concentration ability after water deprivation or desmopressin challenge had not been performed, and the presence of an asymptomatic urinaryconcentration defect could not be excluded. One patient presented additional clinical signs, including chorioretinal colobomas, postaxial polydactyly, lobulated tongue, and cardiomegaly (MTI487) (table 2) .
Other JSRD subgroups.-The screening of the CEP290 gene among a second cohort with MTS yielded mutations in only 2 (2%) among 84 probands, one with classic JS (1 of 42) and one with JS plus NPH (1 of 5). No mutations were found among 21 patients with JS plus ocular involvement, 6 with COACH syndrome, 5 with OFDVI syndrome, and 5 with proven MTS but limited clinical data for subgroup assignment.
Between the two patients with mutations, the one classified as having pure JS presented no overt signs of retinal or renal involvement at age 8 years, and results of kidney ultrasound examination were normal. Yet, the possibility that this child might develop a renal disease phenotype with increasing age cannot be ruled out. The second patient with mutation had urinary-concentration defect but normal vision and no signs of retinal involvement at age 5 years. Both patients were homozygous for the recurrent G1980X mutation.
Discussion
In this study, we identified 17 novel CEP290 truncating mutations, raising to 65 the number of known deleterious alterations found in patients with JSRD and/or LCA. 12, 13, 18, 19 Most mutations appear to be private, with only 12 mutations recurring in two or more families (table 3) . Besides the most common mutation-C998X, which is restricted to LCA-our data show that G1890X represents the second-most frequent CEP290 mutation. Interestingly, this aberration seems to be strictly associated with the JSRD phenotype, since it was never reported in large cohorts of patients with isolated LCA. Yet, other recurrent mutations have been described in families with both JSRD and LCA, making it difficult to establish genotype-phenotype correlates. Of note, whereas mutations causative of isolated LCA appear to be homogeneously distributed throughout the gene, 18, 19 180% of mutations identified in families with JSRD cluster in the second half of the gene. We, as well as others, 13, 19 failed to identify the second mutation in ∼20% of CEP290 families despite extensive sequencing of the whole coding region and canonical splice sites. The possibility that other mutations reside within intronic sequences (as is the case for the recurrent C998X mutation) 18 or represent large genomic rearrangements needs to be further explored.
We found that CEP290 is a major causative gene of definite JSRD-SLS, with demonstrable deleterious mutations detected in half of the patients in this subgroup. The renal disease phenotype was characterized mostly by juvenile NPH, with development of renal failure toward the end of the 1st decade or early in the 2nd decade. However, the age at onset of renal failure was found to be extremely variable, with the youngest patient aged 4 years. Thus, patients with CEP290 mutations can also develop the infantile form of NPH with rapid progression toward renal failure within the first few years of life.
We also identified mutations in three children with retinal blindness but no overt clinical signs of NPH by age 10 years (probable JSRD-SLS). It will be crucial to follow up these patients to evaluate whether they will develop renal disease later in life, to define the prognostic value of CEP290 mutations in predicting NPH. This issue carries important implications for genetics counseling of families and for the setup of early interventional strategies aimed at delaying the progression toward renal failure and minimizing complications such as growth retardation or bone disease.
The ocular phenotype observed in patients with JSRD-SLS is usually characterized by LCA. Yet, patients with rarer cases show no detectable defects in vision within the 1st year of life but later develop a progressive phenotype of retinitis pigmentosa, usually with some residual sight. By screening patients with other non-JSRD-SLS phenotypes, we identified pathogenic mutations in two children with preserved vision and normal ophthalmologic testing at ages 5 and 8 years (MTI012 and MTI587, respectively). Intriguingly, we noticed that these two patients, as well as the single child with JSRD-SLS with retinitis pigmentosa who was not blind at age 6 years (MTI154), were the only three to be homozygous for the recurrent G1890X mutation in exon 41. This correlation holds true also for patients described elsewhere. In fact, of nine patients homozygous for this mutation, only one was reported to have LCA, 12, 13 leading us to speculate that this truncating mutation, through unknown mechanisms, might spare the retina. Conversely, other truncating and splice-site mutations, including the recurrent C998X, are invariably associated with isolated LCA (table 3) , and the rd16 mouse, which carries an inframe 298-aa deletion of CEP290, shows a pure retinal degeneration phenotype. [18] [19] [20] Therefore, there appear to be specific mutations that show predilection for one organ system over another. We excluded the possibility of alternative splicing of implicated exons as a mechanism of this selective organ sparing, because they are present in all mRNAs represented in the UCSC Genome Browser. This observation has not been reported elsewhere for any known genetic disease, to our knowledge, and warrants functional studies of these mutant proteins in specific cell and animal models.
Among the 84 patients with other JSRD subtypes, we identified no mutations other than the ones in the 2 patients without retinopathy. Therefore, it appears that the clinical spectrum of CEP290 mutations is largely restricted to the JSRD-SLS phenotype. It is interesting to note that one patient with mutation with probable JSRD-SLS (MTI487) also presented additional clinical features reminiscent of the OFDVI and COACH subgroups, such as lobulated tongue, postaxial polydactyly of the hands and feet, and bilateral chorioretinal colobomas. Although a definite diagnosis of one of these syndromes could not be made with the current classification system, the clinical spectrum of MTS-associated features does require further delineation.
In some patients with JSRD-SLS with CEP290 mutations, we observed additional peculiar clinical features, expanding the phenotypic spectrum to clearly overlap with other ciliopathies. The first example is the presence in three patients (COR083 and two patients in the work of Sayer et al. 13 ) of occipital (meningo)encephalocele. This neuraltube defect represents a constant feature of MKS, which has been recently shown to be allelic to JSRD at the MKS3 gene. 17 The second example is patient MTI273, a 10-yearold Turkish boy presenting a JSRD-SLS phenotype associated with complete situs inversus. Although this observation may be coincidental, this is unlikely because of the rarity of both conditions and the report of similar phenotypes within the spectrum of ciliopathies. Mutations in NPHP2, which encodes inversin, cause infantile NPH occasionally associated with retinal dystrophy or with situs inversus. 21, 22 Similarly, randomization of left-right bodyaxis symmetry was reported in 4% of Finnish patients with MKS 23 and in a BBS-affected family with mutations in BBS8. 24 Of note, two other patients with CEP290 mutations in our cohort (COR03 and MTI154) presented with congenital heart malformations (atrial and ventricular septal defect, respectively) that are often part of the clinical spectrum of abnormalities observed in situs inversus.
The study of animal models with disrupted ciliary structure or function has highlighted a critical role for cilia in regulating specific developmental pathways of neurulation and left-right axis determination. In mouse embryos lacking KIF3B, a protein essential for intraflagellar transport (IFT) and ciliogenesis, the consequent lack of twirling nodal cilia led to a complex developmental phenotype of growth retardation, randomized left-right axis asymmetry, and neural-tube formation defects. 25 Knockout mice for distinct IFT proteins display neural-tube defects that are consequent to disruption of the sonic hedgehog signaling pathway, [26] [27] [28] whereas a deletion of inversin in mouse or knockdown in zebrafish resulted in renal cystic phenotype with laterality defects. 21, 29 Since these proteins share several domains and have been demonstrated to act in large protein-protein networks, 14 it will be intriguing to investigate how CEP290 possibly interacts with other ciliary proteins to regulate basic developmental mechanisms and sensory functions in multiple tissues.
